BAR is an oral JAK1/JAK2 inhibitor that can be administered, either in mono-therapy or in combination therapy with MTX, at a dosage of 2 or 4 mg once-daily in adult patients with moderate to severe active RA who are intolerant or unresponsive to one or more conventional DMARDs (3–8). Here, JAK2 is linked to rheumatoid arthritis.